Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GRTX..........................................https://stockcharts.com/h-sc/ui?s=GRTX&p=W&b=5&g=0&id=p86431144783
GRTX..........................................https://stockcharts.com/h-sc/ui?s=GRTX&p=W&b=5&g=0&id=p86431144783
Over 11 million in volume with a high of .245 $
Sounds good
As of December 31, 2023, Galera had cash and cash equivalents of $18.3 million. Galera expects that its existing cash and cash equivalents will enable Galera to fund its operating expenses and capital expenditure requirements into the second quarter of 2025.
And some news will be great !
$GRTX - wants to move even higher...funds buying in? Anyone monitoring that? I need to find those links for Institutional reporting
Looks like a lot of people gave up and sold too low...it may punch UP further tomorrow...certainly held gains ah's. News pending?
13G 12% stake. Looks ready. Mc only 7 mill, cash and tangibles 28 mill. No cash needed until 2025. Buyout candidate IMO.
Close Watch: GRTX 8 x 34 + other daily technicals curling up. Now @0.14 - 0.15 > 0.1610 - 0.171(Parabolic SAR) >> 0.32, and then up to 0.50, +233% short-term target price.
TP: 0.25 min 0.50 max and/or 0.42 ave.(short-term TP = 3x or +200% from 0.14-.0.15 current pps) .
Source: 3 stock analysts. Click here.
GRTX...................https://stockcharts.com/h-sc/ui?s=GRTX&p=W&b=5&g=0&id=p86431144783
Why ? do you think it will go higher soon ?
Dumped at .145..TY stock God's...In .0919
Seen this many times.This goose is cooked.Expect chapter 11 in the near future.Good luck and good trading.
You may as well unload now...geez.. what a fiasco
And in the case of IPIX like it is here with Galera, the FDA constantly wants more testing and more testing. But yet for an experimental MRNA shot which scientists and the medical community will not truly know the effects for another 5 years on one’s health, they green light. In my opinion, it’s all about who greases whose palms!!!
Overreaction??? This looks to be going down the route of IPIX. Both of these companies Galera and Innovation Pharma had a product for OM and both of them have been rejected by the FDA. It’s amazing to me the stupidity of how it goes especially since they have nothing that really works right now and patients that develop OM usually have to stop cancer treatments and then decide whether or not to continue once the symptoms subside and heal. And the cost for a severe OM patient to be treated is very, very expensive.
$GRTX where's the guy who was pumping this trash all over iHub?
Next stop is BK and delisting.
Do the company has any IP property for buyout/merger with all the trails cancellations...
Over reaction: GRTX, cash: $28.4 M. "Galera estimates that its balance of cash, cash equivalents and short-term investments as of September 30, 2023 was $28.4 million. or $0.7/share . "
Not bad??? Check out market reaction. Down 50% pre market.
News out, need to do another phase 3 tests and submit holding back other drug to save money… not bad
Should be hearing something this week
It is possible to fill that $2 gap Omega... Depends on how good the news is...
...with Good Weather. lol
Early Christmas 🎄
Gap fill would be excellent.
fda news run to $2 tomorrow??
Yep, I think that it's leaking out that news is coming. Maybe this afternoon or tomorrow???
Think we have seen the bottom...Looking better here
What’s the intended date?
$GRTX According to the FDA guidance document titled “Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Guidance for Industry”, after a Type A meeting, the FDA will provide written feedback to the sponsor or applicant within 14 calendar days of the meeting. This feedback will include a summary of the meeting, any agreements reached during the meeting, and any action items that need to be addressed by either party.
Agreements that could be reached during a Type A meeting include:
Agreement on clinical trial design: The FDA may agree to a sponsor’s or applicant’s proposed clinical trial design.
Agreement on endpoints: The FDA may agree to a sponsor’s or applicant’s proposed endpoints for a clinical trial.
Agreement on statistical analysis: The FDA may agree to a sponsor’s or applicant’s proposed statistical analysis plan for a clinical trial.
Agreement on labeling: The FDA may agree to a sponsor’s or applicant’s proposed labeling for a drug product.
? I sent it the day before.
Give it 10 minutes
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
340
|
Created
|
12/05/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |